His total treatment was five years – the last two of which he was, fortunately, in remission."

24 Apr 2025

Max’s ALL Journey

In June 2008 18-year-old Max England had just finished his A Levels and was looking forward to starting university in the autumn. But it was not to be, as Max started showing strange symptoms which eventually led to a diagnosis of leukaemia. 

“Max went away on a summer vacation with his friends,” said Max’s mum Ann, who now lives in Warsash, Hampshire. “Whilst he was away, he had symptoms of lethargy and one time he fainted. On return from the vacation his lethargy increased to the point he was almost constantly sleeping. Forty-eight hours after he came home we called the doctor. By this time Max was unable to walk to the surgery which was a few miles away and which he normally would have managed easily.” 

The family was living in Bakewell, Derbyshire at the time and Max was immediately sent by ambulance to Royal Hallamshire Hospital in Sheffield where he was given a blood test. Three days later doctors delivered the devastating news to Max and his family that he had acute lymphoblastic leukaemia (ALL). 

“We were so shocked and panicked. Would Max die? Would he live? We just didn’t know. We didn’t know anything much about leukaemia and what the future might hold. In short, we were terrified.” 

Max was kept for the first four weeks in an isolation ward and chemotherapy treatment started immediately.  

Max with Nan, Doreen

“Max’s health fluctuated during this time,” said Max’s dad Steve. “At one point he had a bad reaction to a combination of drugs which led him to have several mini strokes. This in turn led to him losing his speech, which was terrifying. He was on a drugs trial and we learnt that on one previous occasion someone else on the same trial had the same symptoms. The conflicting drugs were rectified and within 24 hours the problem was resolved.” 

Happily, during the last three years of his chemotherapy treatment, Max was at Oxford Brookes University studying for a degree in Planning which he achieved in 2013. Max is now 35 and living life to the full in Teddington, Middlesex, working in London as an estate agent and has regained his health enough to run two London Marathons. He got married in 2023 and he and his wife Katy are expecting their first child in April this year. 

“Strangely Max’s leukaemia was an enriching experience despite the challenges faced,” said Ann. “It made us a very close family unit who appreciated each other for who we are. We had major support from our family and our friends. We took inspiration from Max’s fortitude and the beautiful innocence of his friends from school. Their viewpoint throughout the whole situation was that Max would always be well and so it has proved to be.” 

Related posts

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

18 October 2021

Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021

Leukaemia UK announces five new John Goldman Fellows for 2021 to accelerate progress and stop the disease devastating lives.

UK’s top chefs unite at gastronomic spectacular to raise funds for life-saving leukaemia research

5 July 2023

UK’s top chefs unite at gastronomic spectacular to raise funds for life-saving leukaemia research

Twenty of the most accomplished and innovative chefs from the UK food scene will gather at The Dorchester on Monday 18th September 2023 for ‘Who’s Cooking Dinner?’, a one-of-a-kind night…

This year’s Olive Boles Innovation Award winner announced

13 November 2023

This year’s Olive Boles Innovation Award winner announced

Dr Kevin Rattigan, University of Glasgow, has been selected as this year’s Olive Boles Innovation Award winner – an accolade given to one Leukaemia UK John Goldman Fellow each year….

Clinical trial begins for pioneering new cancer treatment

10 January 2023

Clinical trial begins for pioneering new cancer treatment

Dr Konstantinos Tzelepis was awarded a Leukaemia UK research fellowship in 2020 and has developed a new class of cancer drug with the potential to treat leukaemia.